Ipsen SA represents values of innovation, integrity, and commitment to improving patient lives. With a strong corporate philosophy centered around patient-focused healthcare solutions, Ipsen SA strives to develop and deliver innovative treatments for complex diseases. The company's dedication to research and development, combined with a global network of partners, allows Ipsen SA to make a positive impact on the lives of patients worldwide.

Ipsen SA is primarily present in various countries and regions globally. The company has a strong presence in Europe, with its headquarters based in France. Ipsen also has significant operations in the United States and several other countries across North and South America, including Canada and Brazil. Additionally, Ipsen has a growing presence in Asia, particularly in China and Japan, as well as key markets in the Middle East and Africa. With its widespread footprint, Ipsen SA aims to serve patients and healthcare professionals across multiple regions and provide its pharmaceutical solutions to a diverse and global community.

Some significant milestones achieved by Ipsen SA include the acquisition of Clementia Pharmaceuticals in 2019, expanding its rare diseases portfolio, and the FDA approval of Cabometyx for advanced hepatocellular carcinoma in 2018. Ipsen SA has also made advancements in neurology, with the 2019 FDA approval of Dysport for pediatric lower limb spasticity. Furthermore, Ipsen SA has collaborated with partners to develop innovative treatments, such as the partnership with Exelixis for the development of Cabometyx. These milestones highlight Ipsen SA's commitment to research, development, and expanding treatment options in various therapeutic areas.

Ipsen SA is a renowned pharmaceutical company with a rich history and background. Founded in 1929, Ipsen has grown to become a global leader in specialty care treatments for urology, oncology, and endocrinology. With a strong focus on innovation and research, Ipsen has developed a diverse range of products to address various medical needs. Over the years, the company has expanded its reach to more than 115 countries and collaborates with numerous partners to enhance patient care worldwide. Ipsen's commitment to improving patient outcomes through cutting-edge therapies and its global presence has solidified its position as a trusted name in the pharmaceutical industry.

The main competitors of Ipsen SA in the market include companies such as Novartis, Sanofi, and Merck KGaA.

Ipsen SA is primarily active in the pharmaceutical industry.

Ipsen SA's business model revolves around the development, manufacturing, and commercialization of innovative pharmaceutical products for various therapeutic areas. As a global biopharmaceutical company, Ipsen focuses on specialty care and oncology, offering a diverse portfolio of drugs to address unmet medical needs. They aim to improve patients' lives through effective treatments, cutting-edge research, and collaborations with healthcare professionals. Ipsen's commitment to innovation and patient-centric solutions further strengthens their foothold in the pharmaceutical industry.

Ipsen의 P/E 비율은 12.09입니다.

Ipsen의 P/S 비율은 2.65입니다.

Ipsen에 대한 AlleAktien 품질 점수는 7/10입니다.

예상되는 Ipsen 매출은 3.5 조. EUR입니다.

예상되는 Ipsen 이익은 767.69 백만 EUR입니다.

Ipsen SA is a global pharmaceutical company based in Paris, France. The company specializes in the research, development, manufacturing, and marketing of medications used to treat cancer, neurological diseases, and rare diseases. Ipsen offers a wide range of products divided into three main business areas. 1. Oncology In the field of oncology, Ipsen offers therapies for the treatment of neuroendocrine tumors (NET), prostate cancer, and pancreatic cancer. The company also has a promising pipeline of medications for the treatment of various types of cancer. 2. Neuroscience Ipsen is a leading provider of therapies for the treatment of neurological diseases such as spasticity, cerebral palsy, and migraines. Products in this area include Dysport, an injectable botulinum toxin, as well as numerous other orally-administered medications. 3. Rare Diseases Ipsen has also specialized in the development and marketing of therapies for the treatment of rare diseases. Products in this area include Somatuline for the treatment of acromegaly and neuroendocrine tumors, as well as Increlex for the treatment of short stature. In addition, Ipsen has a strong presence in Europe, North America, and the Asia-Pacific region. The company has built a large network of subsidiaries, distribution partners, and licensees that allows it to market its products worldwide. Ipsen also relies on innovative partnerships and strategic acquisitions to strengthen its market presence. In 2020, the company acquired Clementia Pharmaceuticals, a company specializing in the development of therapies for the treatment of rare bone diseases such as fibrodysplasia ossificans progressiva (FOP). Overall, Ipsen's business model is based on a strong research and development department that focuses on identifying new therapies and improving existing treatment options. The company works closely with medical professionals, academic institutions, and other industry partners. Ipsen also strives for sustainable corporate development by focusing on environmentally-friendly practices and ethical business practices. The company is committed to carbon-neutral production and supports social projects worldwide. Overall, Ipsen has built a robust business model supported by its strong presence in the global market, its products in various therapy areas, and its innovative research and development department.

Ipsen은(는) 연간 번의 배당을 통해 1.2 EUR의 배당금을 지급합니다.

Ipsen의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Ipsen의 ISIN은 FR0010259150입니다.

Ipsen의 WKN은 A0ESMG입니다.

Ipsen의 티커는 IPN.PA입니다.

지난 12개월 동안 Ipsen은(는) 1.2 EUR 의 배당금을 지급했습니다. 이는 약 1.08 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Ipsen은(는) 1.4 EUR의 배당금을 지급할 것으로 예상됩니다.

Ipsen의 현재 배당 수익률은 1.08 %입니다.

Ipsen은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Ipsen은(는) 지난 24년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 1.4 EUR의 배당금이 예상됩니다. 이는 배당수익률 1.26 %에 해당합니다.

Ipsen은 '건강' 섹터에 속합니다.

Ipsen의 마지막 배당금을 1.2 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Ipsen는 1.2 EUR를 배당금으로 지급했습니다.

Ipsen의 배당금은 EUR에 지급됩니다.